Loading…
Iovance Biotherapeutics, Inc. is projected to rise to $4.48 by 2027, a +6% move from its current price of $4.23. IOVA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $4.08 | $4.23 | $4.39 | +0.04% |
| Jul 13 | $4.01 | $4.23 | $4.46 | +0.08% |
| Jul 14 | $3.97 | $4.23 | $4.52 | +0.12% |
| Jul 15 | $3.93 | $4.24 | $4.57 | +0.15% |
| Jul 16 | $3.90 | $4.24 | $4.61 | +0.19% |
| Jul 17 | $3.87 | $4.24 | $4.65 | +0.23% |
| Jul 18 | $3.84 | $4.24 | $4.68 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.84 | $4.24 | $4.68 | +0.27% |
| Week 2 | $3.70 | $4.25 | $4.89 | +0.54% |
| Week 3 | $3.59 | $4.26 | $5.06 | +0.81% |
| Week 4 | $3.51 | $4.28 | $5.21 | +1.08% |
| Week 5 | $3.44 | $4.29 | $5.35 | +1.36% |
| Week 6 | $3.37 | $4.30 | $5.48 | +1.63% |
| Week 7 | $3.32 | $4.31 | $5.60 | +1.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies using autologous tumor infiltrating lymphocytes for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, unresectable, or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen.
The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc.
in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Iovance Biotherapeutics, Inc. (IOVA) is currently priced at $4.31 per share with a market capitalization of $1.92B and is ranked 2024 in the dataset.
The 30-day forecast shows a neutral stance with a low of $2.22, an average of $4.31, and a high of $5.82; the implied ROI is 0 and sentiment is NEUTRAL.
Longer-term forecasts project a bullish trajectory, with the average price climbing to $6.53 by 2030 and continuing higher toward $43.08 by 2050, accompanied by increasing ROIs from 51.4 to 899.6 and a bullish sentiment through the period.
A major floor 22.0% below — a decisive break under it would weaken the trend.
The nearest floor, 10.6% below — buyers have tended to step in here.
The nearest ceiling, 5.0% above — a clean break opens room to run.
A major ceiling 27.9% above — clearing it would confirm fresh momentum.
Key IOVA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IOVA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.28 | Sell | $4.27 | Sell |
| MA 10 | $4.23 | Sell | $4.24 | Sell |
| MA 20 | $4.15 | Buy | $4.17 | Buy |
| MA 50 | $3.95 | Buy | $3.99 | Buy |
| MA 100 | $3.84 | Buy | $3.73 | Buy |
| MA 200 | $3.11 | Buy | $3.54 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.88 | Neutral |
| Stoch RSI (14) | 35.56 | Neutral |
| CCI (20) | 36.70 | Neutral |
| Williams %R (14) | -44.68 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -4.73 | Sell |
| Bollinger %B (20,2) | 0.62 | Neutral |
| Stochastic %K (14) | 55.32 | Neutral |
| TRIX (15) | 0.33 | Buy |
| Awesome (5,34) | 0.17 | Buy |
| Ultimate (7,14,28) | 54.30 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 4.35 | Sell |
| ADX (14) | 9.60 | Neutral |
| ATR (14) | 0.14 | Info |
The 30-day technical picture shows bullish undertones overall, with a 14-day RSI of 60 and a sentiment labeled BULLISH. The 50-day moving average sits at $3.86 and the 200-day moving average at $3.05.
Support is indicated at $3.54 and resistance at $4.44, framing near-term dynamics.
The 30-day price range spans from $3.28 to $5.66, and annualized volatility is 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.22 | $4.23 | $5.66 | 0% | Neutral | |
| $3.45 | $4.48 | $6.24 | +6% | Neutral | |
| $3.62 | $4.90 | $7.15 | +16% | Neutral | |
| $3.80 | $5.32 | $8.07 | +26% | Bullish | |
| $3.90 | $5.62 | $8.79 | +33% | Bullish | |
| $5.22 | $7.74 | $12.43 | +83% | Bullish | |
| $5.81 | $8.83 | $14.53 | +109% | Bullish | |
| $5.36 | $8.35 | $14.05 | +98% | Bullish | |
| $5.69 | $9.08 | $15.57 | +115% | Bullish | |
| $5.52 | $9.00 | $15.73 | +113% | Bullish | |
| $8.59 | $15.55 | $29.32 | +268% | Bullish | |
| $14.77 | $32.30 | $67.96 | +664% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.22 | $4.23 | $5.31 | +0.00% |
| August 2026 | $3.77 | $4.50 | $5.54 | +6.37% |
| September 2026 | $3.64 | $4.38 | $5.48 | -2.63% |
| October 2026 | $3.62 | $4.39 | $5.56 | +0.30% |
| November 2026 | $3.68 | $4.49 | $5.75 | +2.26% |
| December 2026 | $3.56 | $4.38 | $5.66 | -2.47% |
Click any year to see its month-by-month IOVA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IOVA price prediction for 2026 points to an average of $4.23 (low $2.22, high $5.66) — a potential gain of 0% on today's $4.23. Price action looks broadly range-bound.
In 2027, IOVA is projected to trade between $3.45 and $6.24, averaging $4.48 — a potential gain of +6% from today's $4.23. That is up +6% on the projected 2026 average. A consolidation phase looks the most probable path here.
Iovance Biotherapeutics, Inc.'s 2028 outlook centres on $4.90, within a $3.62 to $7.15 range. That is up +9% on the projected 2027 average. That marks a +16% change versus current levels. Price action looks broadly range-bound.
By 2029, IOVA could reach as high as $8.07, with a base case around $5.32 and support toward $3.80 — roughly +26% from $4.23. Buyers look set to stay in control over this stretch.
Expect IOVA to range from $3.90 to $8.79 through 2030. The $5.62 average target implies a +33% move from current prices. That is up +6% on the projected 2029 average. Momentum favours further upside here.
The IOVA price prediction for 2031 points to an average of $7.74 (low $5.22, high $12.43) — a potential gain of +83% on today's $4.23. Buyers look set to stay in control over this stretch.
In 2032, IOVA is projected to trade between $5.81 and $14.53, averaging $8.83 — a potential gain of +109% from today's $4.23. That is up +14% on the projected 2031 average. Momentum favours further upside here.
Iovance Biotherapeutics, Inc.'s 2033 outlook centres on $8.35, within a $5.36 to $14.05 range. That is -5% versus the projected 2032 average. That marks a +98% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, IOVA could reach as high as $15.57, with a base case around $9.08 and support toward $5.69 — roughly +115% from $4.23. Momentum favours further upside here.
Expect IOVA to range from $5.52 to $15.73 through 2035. The $9.00 average target implies a +113% move from current prices. That is -1% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The IOVA price prediction for 2040 points to an average of $15.55 (low $8.59, high $29.32) — a potential gain of +268% on today's $4.23. Momentum favours further upside here.
In 2050, IOVA is projected to trade between $14.77 and $67.96, averaging $32.30 — a potential gain of +664% from today's $4.23. That is up +108% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IOVA today (≈ 236.406619 IOVA) could be worth
$7,636.92
+$6,636.92 (+664%) by 2050 · US Dollar
Based on the average projected IOVA price of $32.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IOVAwould be worth at today's price.
$1,000 invested in IOVA on Jul 10, 2025 (≈ 518.134729 IOVA) would be worth
$2,191.71
+$1,191.71 (+119.2%) today · 2.19× · US Dollar
Based on a IOVA entry price of $1.93 vs. today's $4.23.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.31 | $981.44 | -1.9% |
| 1 month ago | $3.78 | $1,119.05 | +11.9% |
| 3 months ago | $3.7 | $1,143.24 | +14.3% |
| 6 months ago | $2.4 | $1,762.5 | +76.2% |
| 1 year ago | $1.93 | $2,191.71 | +119.2% |
| All time (5.0y) ago | $25.3 | $167.19 | -83.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IOVA forecast.
Our base-case forecast reaches $8.50 around 2032.
Implied market cap at $8.50: $3.8B
The multi-year forecast highlights substantial upside potential. In 2030, the avg price is forecast at $6.53 with a min of $4.40 and a max of $10.49, and the ROI is 51.4; sentiment for this horizon is BULLISH.
For 2040, the avg price is forecast at $19.86 with a min of $10.29 and a max of $38.99, and the ROI is 360.7; sentiment remains BULLISH.
In 2050, the avg price is forecast at $43.08 with a min of $19.39 and a max of $94.98, and the ROI is 899.6; sentiment is BULLISH.
These figures are estimates reflecting a bullish long-term outlook, but they are not guarantees and could be affected by market conditions and other factors.
Tap a question to reveal the answer.
Avg $6.53; min $4.40; max $10.49; ROI 51.4; sentiment BULLISH.
The 2026 forecast shows avg $4.31 with ROI 0 and NEUTRAL sentiment; subsequent years show rising averages and positive ROIs (2027 avg $4.75, ROI 10.3; 2028 avg $5.25, ROI 21.9; 2029 avg $5.76, ROI 33.7; 2030 avg $6.53, ROI 51.4), with a bullish trajectory indicated in later years.
Yes. The forecast lists a max of $10.49 in 2030, and higher maxes in later years (2031 $15.17; 2032 $17.60; 2033 $17.16; 2034 $19.23; 2035 $19.50).
Current price $4.31; Market cap $1.92B.
2040 avg $19.86, ROI 360.7; 2050 avg $43.08, ROI 899.6.
Iovance Biotherapeutics, Inc. Community Discussion
0Share your Iovance Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.